Active Ingredient History

NOW
  • Now
Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon administration the decitabine is metabolized to the active phosphorylated metabolite which is incorporated into DNA and thus inhibits DNA methyltransferase (decitabine deplete DNMT1).   NCATS

  • SMILES: NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2
  • InChIKey: XAUDJQYHKZQPEU-KVQBGUIXSA-N
  • Mol. Mass: 228.2053
  • ALogP: -2.14
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$1.4872 - $182.2100
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( decitabine (dacogen), cedazuridine - other name: decitabine and cedazuridine )
2'-deoxy-5-azacytidine | 4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-one | 5-aza-2'-deoxycytidine | 5-azadeoxycytidine | 5-aza-deoxycytidine | 5-deoxyazacytidine | azadc | azadc compound | dac | dacogen | decitabine | decitabine mesilate | decitabine mesylate | dezocitidine | jnj-30979754 | nsc 127716 | nsc-127716

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue